Not exact matches
She even
found evidence that the devils» immune systems were occasionally performing this interferon - gamma trick themselves: In some instances,
tumor cells near the edge of the
tumor, in close proximity to white blood cells, showed MHC
antigens that cells farther within the
tumor mass lacked.
In collaboration with the group of Valerian Kagan, Ph.D., D.Sc., at the University of Pittsburgh, Gabrilovich and colleagues analyzed in great detail the events that take place in the DCs from
tumor - bearing mice models and
found that impaired cross-presentation, which occurred in the presence of
tumor - derived factors, was associated with defective trafficking of the
antigen - MHC complex to the cell surface.
Hu14.18 K332A is a laboratory - produced antibody designed to activate the immune response against
tumor cells by recognizing and binding to an
antigen found on the surface of most neuroblastoma
tumor cells.
Antonio Lanzavecchia
finds that efficient presentation of soluble
antigen by cultured human dendritic cells is maintained by granulocyte / macrophage colony - stimulating factor plus interleukin 4 and downregulated by
tumor necrosis factor alpha.
Cancerous
tumors and embryonic tissues have been
found to share many of the same
antigens, which are detected by the immune system through antibodies.
Our immuno - oncology product candidates are being developed in two separate approaches: one that targets specific
antigens and / or epitopes (such as CMB305 and in our neoantigen collaboration); and an alternative approach that leverages the endogenous
antigens found in the
tumor microenvironment via intratumoral immunization (such as G100).
About G100: G100 is Immune Design's first product candidate solely generated from the GLAAS ® platform and is designed to leverage the range of endogenous
antigens (including neoantigens)
found in the
tumor microenvironment to create a systemic anti-
tumor immune response from local injection.